tool name

close
tool goes here

Shipments stopped of generic antidepressant

Teva Pharmaceuticals has stopped shipping its generic version of a popular antidepressant after a federal analysis showed the pill does not work properly.

Published: Oct. 4, 2012 at 12:05 a.m. PDT
0 comments

Teva Pharmaceuticals has stopped shipping its generic version of a popular antidepressant after a federal analysis showed the pill does not work properly.

The FDA said Wednesday it asked Teva to withdraw Budeprion XL 300 after new testing showed the drug releases its key ingredient faster than the original drug Wellbutrin XL 300, made by GlaxoSmithKline.

A spokeswoman for Teva said the company stopped shipping the drug last Thursday. The action contradicts the FDA’s previous update on the issue in 2008, when regulators said the drugs are essentially the same. That review came after hundreds of patients complained that Teva’s drug did not work as well or caused side effects such as headaches, anxiety and insomnia.

In 2007, the website ConsumerLab published an analysis of the two drugs, indicating Budeprion XL released 34 percent of its active ingredient in just two hours, compared to 8 percent for the original drug.

JOIN THE DISCUSSION | Register here

We welcome comments. Please keep them civil, short and to the point. ALL CAPS, spam, obscene, profane, abusive and off topic comments will be deleted. Repeat offenders will be blocked. Thanks for taking part — and abiding by these simple rules. A thorough explanation of rules of conduct can be found in our Terms of Service. If you have any questions, including why your comment may not be showing immediately after you submit it, be sure to visit the commenting FAQ.

CONTESTS

Similar stories

  • FDA denies request to block generic painkiller

    In a surprise move Friday, federal health regulators denied a request by Endo Health Solutions to block generic versions of its painkiller Opana ER, which the company argued are more easily abused than its branded product.

  • Florida women play key role in emergency birth-control case

    The long and sweeping movement to broaden access to emergency contraception — which may culminate soon in girls and women of all ages having over-the-counter access — has been led, in part, by a group of Florida grassroots activists — students, mothers, daughters.

  • Wrigley takes new caffeinated gum off market

    A Food and Drug Administration investigation into the safety of caffeine-added foods has prompted Wrigley to take its new caffeinated gum off the market for the time being.

  • FDA has safety concerns with Merck insomnia drug

    Federal health regulators say an experimental insomnia drug from Merck can help patients fall asleep, but it also carries worrisome side effects, including daytime drowsiness and suicidal thinking.

  • APNewsBreak: Wrigley halts caffeinated gum

    Wrigley says it is taking a new caffeinated gum off the market temporarily as the Food and Drug Administration investigates the safety of added caffeine.